Drug Profile
Research programme: agammaglobulinaemia tyrosine kinase inhibitors - Aurigene Oncology
Alternative Names: BTK inhibitors - Aurigene OncologyLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Autoimmune-disorders in India
- 28 Aug 2018 No recent reports of development identified for research development in Inflammation in India
- 15 Jul 2014 Early research in Autoimmune disorders in India (unspecified route)